These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 16912263)
1. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. Hassett MJ; O'Malley AJ; Pakes JR; Newhouse JP; Earle CC J Natl Cancer Inst; 2006 Aug; 98(16):1108-17. PubMed ID: 16912263 [TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714 [TBL] [Abstract][Full Text] [Related]
3. Re: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. Russo A; Autelitano M; Bisanti L J Natl Cancer Inst; 2006 Dec; 98(24):1826-7. PubMed ID: 17179484 [No Abstract] [Full Text] [Related]
4. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Pelletier EM; Shim B; Goodman S; Amonkar MM Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662 [TBL] [Abstract][Full Text] [Related]
6. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Bennett CL; Calhoun EA Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690 [TBL] [Abstract][Full Text] [Related]
7. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. Adjuvant Breast Cancer Trials Collaborative Group J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995 [TBL] [Abstract][Full Text] [Related]
8. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. Shih YC; Xu Y; Cormier JN; Giordano S; Ridner SH; Buchholz TA; Perkins GH; Elting LS J Clin Oncol; 2009 Apr; 27(12):2007-14. PubMed ID: 19289624 [TBL] [Abstract][Full Text] [Related]
9. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Oestreicher N; Ramsey SD; McCune JS; Linden HM; Veenstra DL Cancer; 2005 Nov; 104(10):2054-62. PubMed ID: 16216002 [TBL] [Abstract][Full Text] [Related]
10. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. Baxter NN; Durham SB; Phillips KA; Habermann EB; Virning BA J Am Geriatr Soc; 2009 Mar; 57(3):403-11. PubMed ID: 19278395 [TBL] [Abstract][Full Text] [Related]
11. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults. Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388 [TBL] [Abstract][Full Text] [Related]
12. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States. Fu AZ; Jhaveri M J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589 [TBL] [Abstract][Full Text] [Related]
13. Economic outcomes of breast cancer survivorship: CALGB study 79804. Hensley ML; Dowell J; Herndon JE; Winer E; Stark N; Weeks JC; Paskett E Breast Cancer Res Treat; 2005 May; 91(2):153-61. PubMed ID: 15868443 [TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization and costs of patients with rosacea in an insured population. Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697 [TBL] [Abstract][Full Text] [Related]
15. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
16. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. Hershman DL; Buono D; McBride RB; Tsai WY; Joseph KA; Grann VR; Jacobson JS J Natl Cancer Inst; 2008 Feb; 100(3):199-206. PubMed ID: 18230795 [TBL] [Abstract][Full Text] [Related]
17. The financial burden of cancer: estimates from a study of insured women with breast cancer. Arozullah AM; Calhoun EA; Wolf M; Finley DK; Fitzner KA; Heckinger EA; Gorby NS; Schumock GT; Bennett CL J Support Oncol; 2004; 2(3):271-8. PubMed ID: 15328826 [TBL] [Abstract][Full Text] [Related]
18. Work absence after breast cancer diagnosis: a population-based study. Drolet M; Maunsell E; Mondor M; Brisson C; Brisson J; Mâsse B; Deschênes L CMAJ; 2005 Sep; 173(7):765-71. PubMed ID: 16186583 [TBL] [Abstract][Full Text] [Related]
19. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Tina Shih YC; Xu Y; Elting LS Cancer; 2007 Aug; 110(3):678-85. PubMed ID: 17567835 [TBL] [Abstract][Full Text] [Related]
20. Assessing the economic burden of breast cancer in a US managed care population. Barron JJ; Quimbo R; Nikam PT; Amonkar MM Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]